
    
      PRIMARY OBJECTIVE:

      I. To determine the safety, maximum tolerated dose (MTD), and recommended phase 2 dose (RP2D)
      of trifluridine and tipiracil hydrochloride (trifluridine/tipiracil [FTD/TPI]) in combination
      with talazoparib tosylate (talazoparib) in patients with advanced colorectal (CRC) or
      gastroesophageal (EGC) adenocarcinoma.
    
  